Malignant News and Research

RSS

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Whitehead Institute scientists have identified a genetic cause of a facial disorder known as hemifacial microsomia (HFM). The researchers find that duplication of the gene OTX2 induces HFM, the second-most common facial anomaly after cleft lip and palate.

12 May 2014

Veracyte's revenue increases 71% to $7.5 million in Q1 2014

Veracyte, Inc. today reported financial results for the first quarter ended March 31, 2014, and provided an update on recent business progress. For the first quarter of 2014, revenue was $7.5 million, an increase of 71%, compared to $4.4 million for the first quarter of 2013.

9 May 2014

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut.

9 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited.

6 May 2014

NCCN publishes new patient resource for stage 0 breast cancer

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation®, announces the availability of the NCCN Guidelines for Patients: Breast Cancer Stages 0 - IV—the latest addition to the library of NCCN Guidelines for Patients available online free-of-charge at NCCN.org/patients.

6 May 2014

Study reveals how ovarian cancer metabolism changes between early, late stages

A Rice University-led analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize, or spread to other parts of the body. The study also suggests how ovarian cancer treatments can be tailored based on the metabolic profile of a particular tumor.

6 May 2014

New research reveals that eczema may lower skin cancer risk

Eczema caused by defects in the skin could reduce the risk of developing skin cancer, according to new research by King's College London. The immune response triggered by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.

6 May 2014

Researchers analyze living cells quickly and accurately using Raman spectroscopy

In order to investigate inflammation, tumors or stem cells, medical practitioners analyze living cells. Non-invasive optical procedures such as Raman spectroscopy accelerate this procedure. Researchers have now developed it to industrial scale.

5 May 2014

$RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer$

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

2 May 2014

Possible link between aggressive prostate cancer and vitamin D deficiency

Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in European-American and African-American men who underwent their first prostate biopsy because of abnormal prostate-specific antigen (PSA) and/or digital rectal examination (DRE) test results, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

1 May 2014

U of L School of Medicine researchers use breath analysis to detect lung cancer

Researchers at the University of Louisville School of Medicine are using breath analysis to detect the presence of lung cancer. Preliminary data indicate that this promising noninvasive tool offers the sensitivity of PET scanning, and has almost twice the specificity of PET for distinguishing patients with benign lung disease from those with early stage cancer.

30 Apr 2014

Two internationally known scholars join Huntsman Cancer Institute

Two internationally known scholars, one in the field of cancer prevention and the other in the field of molecular biology, will join Huntsman Cancer Institute (HCI) at the University of Utah as early as Sept. 1.

29 Apr 2014

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

25 Apr 2014

Study explains biological processes of malignant cancer cells

Cancer cells may be known for their uncontrollable growth and spread, but they also differ from normal tissue in another manner: how they produce energy.

22 Apr 2014

Small gene embedded in large gene contributes to development of acute myeloid leukemia

A small gene that is embedded in a larger, well-known gene is the true leukemia-promoting force usually attributed to the larger gene, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

22 Apr 2014

Twenty years data analysis shows patients treated with HIPEC may have improved survival rates

Meaningful long-term survival is possible for selected patients suffering from advanced cancer of the abdomen when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, or HIPEC, according to a first-of-its-size analysis by physicians at Wake Forest Baptist Medical Center.

21 Apr 2014

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

17 Apr 2014

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications.

15 Apr 2014

Malignant News and Research

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Veracyte's revenue increases 71% to $7.5 million in Q1 2014

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

NCCN publishes new patient resource for stage 0 breast cancer

Study reveals how ovarian cancer metabolism changes between early, late stages

New research reveals that eczema may lower skin cancer risk

Researchers analyze living cells quickly and accurately using Raman spectroscopy

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Possible link between aggressive prostate cancer and vitamin D deficiency

U of L School of Medicine researchers use breath analysis to detect lung cancer

Two internationally known scholars join Huntsman Cancer Institute

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Study explains biological processes of malignant cancer cells

Small gene embedded in large gene contributes to development of acute myeloid leukemia

Twenty years data analysis shows patients treated with HIPEC may have improved survival rates

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News